மைக் பிஏக News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from மைக் பிஏக. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In மைக் பிஏக Today - Breaking & Trending Today
Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ... apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Keros Therapeutics Appoints Si - GuruFocus.com gurufocus.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gurufocus.com Daily Mail and Mail on Sunday newspapers.
Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Share: DUBLIN, Ireland and TREVOSE, Pa., June 03, 2021 (GLOBE NEWSWIRE) Strongbridge Biopharma plc, (NASDAQ:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,020,393 entitled, Methods of Treating Disease with Levoketoconazole which covers a method of treating Cushing s syndrome patients with RECORLEV ® (levoketoconazole) who also take metformin for Type 2 diabetes. The term of the U.S. patent will expire on March 2, 2040. This will be the third patent issued in the U.S. relating to RECORLEV. The first, U.S. Patent No. 9,198,906, covers methods of reducing C-reactive protein levels and systemic inflammation through administration of a once-daily dose of RECORLEV and will expire on December 29, 2030. The second, U.S. patent No. 9,918,984, cover ....
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate . Strongbridge Biopharma plcMay 12, 2021 GMT ~ Reports KEVEYIS ® (dichlorphenamide) First Quarter 2021 Revenue of $8.4 Million, a 25 Percent Increase Compared to $6.7 Million of Revenue During First Quarter of 2020 ~ ~ Reiterates Full-Year 2021 KEVEYIS (dichlorphenamide) Revenue Guidance of Approximately $34 Million to $36 Million ~ ~ Awaiting Day 74 Letter from U.S. Food & Drug Administration (FDA) for the Company’s New Drug Application (NDA) Submission for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome ~ ~ Receives Notification from United States Patent and Trademark Office that it has Entered a Notice of Allowance Covering a Method of Treating Patients with Cushing’s Syndrome with RECORLEV® (levoketoconazole) ....